title: Impact of HLA-E gene polymorphism on HLA-E expression in tumor cells and prognosis in patients with stage III colorectal cancer.
abstract: Human leukocyte antigen (HLA)-E can contribute to the escape of cancer cells from host immune mechanisms. However, it is unknown whether HLA-E gene polymorphisms might play a role in cancer immune escape. This study aimed to evaluate the correlation between HLA-E gene polymorphisms and HLA-E expression in tumor tissue and determine the effects on clinical outcome of patients with stage III colorectal cancer. Two hundred thirty patients with stage III colorectal cancer were enrolled. HLA-E expression was detected in patient-derived tumor tissues with immunohistochemistry. HLA-E gene alleles in tumor tissues were detected with the polymerase chain reaction-sequence-specific primer method. In colorectal cancer tissue and in the normal tissue adjacent to the tumor, the HLA-E expression rates were 72.2 and 15.1 %, respectively (P < 0.05). Patients with overexpression, low expression, and no expression of HLA-E exhibited disease-free survival of 55.3, 72.9, and 72.1 %, respectively. Patients with HLA-E overexpression exhibited the lowest long-term survival rate. No relationship was observed between the type of HLA-E gene polymorphism and its expression level in tumor tissues; moreover, no polymorphisms appeared to affect the long-term survival of patients with colorectal cancer. The type of HLA-E polymorphism did not have an impact on HLA-E expression in tumors or the prognosis in patients with stage III colorectal cancer. However, the level of HLA-E expression in tumor tissue strongly predicted long-term survival in these patients.
authors: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, China. zhenzj@sysucc.org.cn
authors: Zi-Jun
authors: ZJ
authors: Zhen
authors: Jia-Yu
authors: JY
authors: Ling
authors: Yue
authors: Y
authors: Cai
authors: Wen-Biao
authors: WB
authors: Luo
authors: You-Jian
authors: YJ
authors: He
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D015179:Colorectal Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D005838:Genotype; D015395:Histocompatibility Antigens Class I / Q000096:biosynthesis / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009367:Neoplasm Staging; D011110:Polymorphism, Genetic; D011379:Prognosis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000097625:HLA-E Antigens
chemical_list: D014408:Biomarkers, Tumor; D015395:Histocompatibility Antigens Class I; D000097625:HLA-E Antigens
references: Hum Immunol. 2005 Jan;66(1):1-12
references: 15620456
references: J Immunol. 2006 Sep 1;177(5):3100-7
references: 16920947
references: Hum Immunol. 1997 Jan;52(1):33-40
references: 9021407
references: Immunogenetics. 2008 Aug;60(8):439-47
references: 18545995
references: J Clin Invest. 2002 Nov;110(10):1515-23
references: 12438449
references: J Neuropathol Exp Neurol. 2005 Jun;64(6):523-8
references: 15977644
references: Immunology. 2007 May;121(1):1-14
references: 17386080
references: J Immunol. 2010 Dec 15;185(12):7452-9
references: 21057081
references: Tissue Antigens. 2012 Jul;80(1):26-35
references: 22486789
references: J Clin Oncol. 2007 Jun 20;25(18):2573-9
references: 17577036
references: Mod Pathol. 2007 Feb;20(2):256-66
references: 17192787
references: J Clin Oncol. 2011 Apr 20;29(12):1547-55
references: 21422427
references: J Biol Chem. 2003 Feb 14;278(7):5082-90
references: 12411439
references: Tissue Antigens. 2002 Sep;60(3):206-12
references: 12445303
references: Innate Immun. 2009 Apr;15(2):91-100
references: 19318419
references: Tissue Antigens. 2007 Apr;69 Suppl 1:132-5
references: 17445187
references: Cancer Immunol Immunother. 2012 Jun;61(6):803-16
references: 22072317
references: J Immunol. 1999 Jan 1;162(1):305-13
references: 9886400
references: Tissue Antigens. 2012 Jan;79(1):15-24
references: 22050290
references: Lancet Oncol. 2007 Oct;8(10):898-911
references: 17888735
references: Hum Immunol. 2005 Feb;66(2):164-9
references: 15695002
references: J Exp Med. 2008 Mar 17;205(3):725-35
references: 18332182
references: Hum Immunol. 2000 Nov;61(11):1150-6
references: 11137220
references: Pathology. 2002 Apr;34(2):133-7
references: 12009094
references: Int J Cancer. 2012 Aug 15;131(4):855-63
references: 21953582
references: Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10656-61
references: 21670276
references: Neuropathology. 2011 Apr;31(2):129-34
references: 20667016
references: Leukemia. 2008 May;22(5):998-1006
references: 18288133
references: Tissue Antigens. 2004 Nov;64(5):588-92
references: 15496202
references: Immunol Rev. 1998 Jun;163:129-38
references: 9700506